Asgard Therapeutics is at the forefront of cancer immunotherapy, focusing on innovative direct cell reprogramming technologies. Their lead program, AT-108, is a pioneering gene therapy designed to convert tumor cells into conventional Type 1 dendritic cells (cDC1s), which are essential for effective anti-tumor immunity. This approach allows for the reprogramming of cancer cells within the patient's body, enabling them to present specific cancer antigens to the immune system. By doing so, AT-108 aims to trigger personalized and robust immune responses against tumors, overcoming many of the logistical and manufacturing challenges associated with traditional cell-based therapies.

The technology behind AT-108 utilizes a replication-deficient adenoviral vector to deliver three transcription factors into tumor cells, effectively rewiring their gene expression. This transformation not only enhances the immunogenicity of the tumor cells but also promotes the activation and infiltration of cytotoxic T cells, leading to systemic anti-tumor effects. Asgard's approach has shown promising results in preclinical studies, demonstrating strong anti-tumor responses and the potential for long-lasting immunity, even in challenging tumor microenvironments. The company is actively advancing AT-108 towards clinical trials, supported by significant funding and collaborations with leading research institutions.

Sweden

Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient.

Asgard Therapeutics

Company Details